NHMRC Glaucoma Guidelines - ANZGIG
NHMRC Glaucoma Guidelines - ANZGIG
NHMRC Glaucoma Guidelines - ANZGIG
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>NHMRC</strong> GUIDELINES FOR THE SCREENING, PROGNOSIS, DIAGNOSIS, MANAGEMENT AND PREVENTION OF GLAUCOMA<br />
Chapter 5 – Prognosis: understanding the natural history<br />
The Collaborative Normal Tension <strong>Glaucoma</strong> Study (1998) identified a 10-fold range in deterioration<br />
rates in VF from -0.2dB/year to -2.0 dB/year, illustrating the marked variability in natural rates<br />
of deterioration in NTG. This variability prevents prediction of individual rates of VF loss.<br />
These guidelines provide recommendations for a standard process for monitoring in Chapter 8.<br />
Evidence Statements<br />
• Evidence strongly supports reducing intraocular pressure in patients with normal tension glaucoma, in<br />
order to preserve the visual field and reduce glaucomatous progression rates.<br />
• Evidence strongly supports monitoring rates of visual field loss in patients with normal tension glaucoma.<br />
Communication with patients<br />
While lowering intraocular pressure slows or halts glaucoma progression, all interventions carry<br />
risk. Potential benefit and possible harm (the therapeutic index) need to be balanced carefully,<br />
with patient involvement where possible, in decision making.<br />
Ocular hypertension<br />
The majority of patients with OH will not progress to POAG in the short term (90% will not convert<br />
within five years) (Burr, Mowatt, Herandez et al 2007). Within five years however, 9.5% of untreated<br />
patients will progress to POAG, compared to 4.4% of medically treated patients (Burr et al 2007).<br />
Patients with an initial intraocular pressure (IOP) of 26mmHg or more are more at-risk of<br />
progressing to glaucoma. Conversion time to POAG from OH is significantly shorter for individuals<br />
not undergoing treatment (Fleming, Whitlock, Beil et al 2005).<br />
It is reported that 37% of optic nerve fibres need to be lost before a field defect can be identified<br />
on VF testing (Kerrigan, Zack, Quigley et al 1997; Quigley, Nickells, Kerrigan et al 1995).<br />
Therefore undetected progression may be occurring in untreated individuals because current<br />
standard automated perimetry is insufficiently sensitive to detect functional loss at this stage of<br />
disease. This highlights the need for using the most sensitive methods of VF testing and structural<br />
assessments for patients with OH.<br />
Risk factors for progression to glaucoma include elevated IOP, increased cup:disc ratio, older<br />
age, and thinner corneas (Friedman, Wilson, Liebmann et al 2004). There is also strong evidence<br />
that central corneal thickness (CCT) is a reliable indicator for the risk of conversion from OH<br />
to glaucoma.<br />
The strongest evidence links the likelihood of conversion to poorly controlled and high IOP. In the<br />
Ocular Hypertension Treatment Study (Gordon, Beiser, Brandt et al 2002; Gordon, Torri, Miglior et<br />
al 2007; Kass, Huerer, Higginbotham et al 2002), univariate and multivariate analyses identified that<br />
every 1mmHg increase in mean IOP level was associated with a 10% increased risk of conversion<br />
from OH to glaucoma. These guidelines provide recommendations for a standard format for<br />
assessing risk (see Chapter 6) and monitoring (see Chapter 8).<br />
40 National Health and Medical Research Council